Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy Designation for PM359 for the Treatment of Chronic Granulomatous Disease
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
Goldera Expands High-Grade E1 Gold Discovery with Two New Parallel Structures Ahead of Planned Q4 Drilling at Egan Gold Project
LaFleur Minerals Intersects 6.05 g/t Au over 8.00 Metres, Including 14.96 g/t Au over 3.00 Metres, Near Surface at Bartec Target and Identifies Additional New Targets at the Swanson Property
Oreterra CEO Letter to Shareholders Provides Forward Guidance on Trek South Drill Results in Advance of Assays
